

Bevacizumab GOG-0218

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



No QoL benefit



**Serious and disabling adverse effects**



**Other adjustments**



Bevacizumab GOG-0218

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Gynaecological Malignancies

Therapeutic Indication: Front-line treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

Experimental Arm: Bevacizumab + Carboplatin + paclitaxel

Control Arm: Paclitaxel + carboplatin (6 cycles)

